What does "legal" actually mean for a peptide company?

A peptide business is not legal or illegal as a category — it is legal or illegal one product, one buyer, and one transaction at a time. The defensible model is narrow: lawfully marketable peptide drug products moving from a verified FDA-regulated source into verified licensed medical channels, with no consumer-direct sales, no "research use" workaround, no off-label promotion, and complete auditability.

The framing that gets companies frozen or worse is "peptide companies sell peptides to doctors, and doctors sell them to patients." That still describes unapproved drug distribution unless the product, seller, buyer, prescription path, labeling, marketing, supply chain, and payment flow each independently fit a lawful pathway.

The five things every compliant peptide company gets right

These are the load-bearing controls. Miss one and the rest does not save you:

• Lawful product pathway for every SKU — FDA-approved drug, 503B outsourcing-facility office stock, 503A patient-specific prescription, or an IND research framework. No gray-market APIs.
• The regulated party is the merchant of record for the drug — your company is compliance and payments infrastructure, not the reseller of the medicine.
• Marketing is B2B professional education only — no therapeutic, performance, anti-aging, or weight-loss claims; no testimonials, before/after photos, or influencer codes.
• Provider buyers are credentialed beyond an NPI — active license, scope of practice, dispensing authority, and a clean disciplinary record, checked against the product and the state.
• Everything is auditable — SKU, lot, clinic, patient prescription where applicable, and payment — and an examiner-ready file can be produced fast.

What kind of entity should a peptide company be?

The cleanest structure separates commercial operations from clinical decisions. Your company supplies audited infrastructure — ordering, compliance checks, documentation, logistics coordination, payment routing — and earns fixed, fair-market-value fees that are not tied to prescription volume where healthcare-fraud laws are implicated.

Taking title to the drug and reselling it, collecting patient money for a physician's clinical service, or bundling marketing, referrals, payments, and product supply together are exactly the patterns regulators read as steering prescriptions or practicing medicine without authority.

Why payments are the forcing function

A sponsor bank, acquirer, and card-brand examiner will all ask the same question: is this program boardable right now? They want to see the catalog, the claims on your URLs, the MCC, the credentialing controls, and the recall system. A program that cannot produce that file does not get a durable merchant account — it gets a short-notice termination later.

That is why getting payments right is not the last step. The discipline a bank requires — lawful catalog, no claims, credentialed buyers, lot traceability — is the same discipline that keeps you on the right side of the FDA and the FTC.